Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Comparison of aripiprazole and risperidone effectiveness in first episode non-af...
Journal Information
Vol. 14. Issue 3.
Pages 157-163 (July - September 2021)
Share
Share
Download PDF
More article options
ePub
Vol. 14. Issue 3.
Pages 157-163 (July - September 2021)
Clinical trials and protocols
Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)
Visits
...
Mayoral-van Son J.a,1,
Corresponding author
, Marcos Gómez-Revueltab,1,
Corresponding author
marcos.gomezr@scsalud.es

Corresponding authors.
, Rosa Ayesa-Arriolab, Javier Vázquez-Bourgónb, Víctor Ortiz-García de la Fozb, Miguel Ruiz-Veguillaa, Nathalia Garridoa, Diana Tordesillas-Gutiérrezb, Esther Setién-Suerob, Benedicto Crespo-Facorroa
a Hospital Universitario Virgen del Rocío, Departamento de Psiquiatría, Universidad de Sevilla, IBiS, CIBERSAM, Sevilla, Spain
b Hospital Universitario Marques de Valdecilla, Departamento de Psiquiatría, Universidad de Cantabria, IDIVAL, CIBERSAM, Santander, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Abstract
Background

Selecting the most effective treatment represents a critical challenge with the potential of modifying the long-term prognosis of individuals suffering a first break of psychosis. Head-to-head clinical trials comparing effectiveness among antipsychotic drugs in individuals with a first-episode of non-affective psychosis (FEP) are scarce.

Methods

The rationale and design of a 3 phases clinical trial (PAFIP-3, NCT02305823) comparing the effectiveness of aripiprazole and risperidone, and to additionally assess the benefits of an early use of clozapine in primary treatment-resistant patients is reported. The design encompasses of 5 work packages (medication algorithm, cognitive functioning, psychoeducation/vocational functioning, imaging and biological markers) addressing critical issues and needs of first episode psychosis individuals and their cares. The primary outcome measure was treatment effectiveness assessed by all-cause treatment discontinuation rate.

Results

266 individuals have been included in the randomization study phase I (risperidone vs. aripiprazole). At 3 months, the retention rate was of 94% (249/266), 48(19.3%) patients have gone through phase II (olanzapine treatment), and 7(2.8%) entered the clozapine phase (phase III).

Discussion

The PAFIP 3 clinical trial may provide relevant information about clinical guidelines to optimally treat patients with a first episode of non-affective psychosis and the benefits and risks of an early use of clozapine in treatment resistant patients.

Clinicaltrials.gov: NCT02305823.

Keywords:
Clozapine
First-episode psychosis
Schizophrenia
Effectiveness
Antipsychotics

Article

These are the options to access the full texts of the publication Revista de Psiquiatría y Salud Mental (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista de Psiquiatría y Salud Mental (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos